Human papillomavirus type 11 L1 capsid protein antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Human papillomavirus type 11 L1 capsid protein antigen
Accession Number
DB10300
Description

Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • L1 protein, Human papillomavirus type 11 Vaccine
  • Recombinant human papillomavirus type 11 L1 protein

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
GardasilHuman papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 6 L1 capsid protein antigen (20 ug/0.5mL)Injection, suspensionIntramuscularMerck Sharp & Dohme Corp.2006-06-08Not applicableUs
GardasilHuman papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 6 L1 capsid protein antigen (20 ug/0.5mL)Injection, suspensionIntramuscularRemedy Repack2014-02-132015-02-11Us
GardasilHuman papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 6 L1 capsid protein antigen (20 ug/0.5mL)Injection, suspensionIntramuscularMerck Sharp & Dohme Corp.2006-06-08Not applicableUs
GardasilHuman papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 6 L1 capsid protein antigen (20 mcg)SuspensionIntramuscularMerck Ltd.2006-08-162019-08-22Canada
GardasilHuman papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 6 L1 capsid protein antigen (20 ug/0.5mL)Injection, suspensionIntramuscularA-S Medication Solutions2006-06-08Not applicableUs
Gardasil 9Human papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (60 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 31 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 33 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 45 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 52 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 58 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 6 L1 capsid protein antigen (30 ug/0.5mL)Injection, suspensionIntramuscularMerck Sharp & Dohme Corp.2014-12-10Not applicableUs
Gardasil 9Human papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (60 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 31 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 33 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 45 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 52 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 58 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 6 L1 capsid protein antigen (30 ug/0.5mL)Injection, suspensionIntramuscularMerck Sharp & Dohme Corp.2014-12-10Not applicableUs
Gardasil 9Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (60 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 31 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 33 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 45 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 52 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 58 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 6 L1 capsid protein antigen (30 mcg)SuspensionIntramuscularMerck Ltd.2015-03-18Not applicableCanada
Gardasil 9Human papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (60 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 31 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 33 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 45 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 52 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 58 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 6 L1 capsid protein antigen (30 ug/0.5mL)Injection, suspensionIntramuscularA-S Medication Solutions2014-12-10Not applicableUs

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
Z845VHQ61P
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910486
RxNav
798262

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionAnti-HPV Antibody Patterns / Cervical Cancers / Cervical HPV Infection / Sexually Transmitted Infections (STIs)1
4Active Not RecruitingPreventionCervical Cancers / Cervical Precancerous Lesions1
4Active Not RecruitingPreventionComplication of Transplanted Liver / Human Papillomavirus-Related Carcinoma / Late Complication From Kidney Transplant1
4Active Not RecruitingPreventionPapillomavirus Infections1
4CompletedOtherHealthy Volunteers1
4CompletedPreventionAdenocarcinoma in Situ / Cervical Cancers / Cervical Intraepithelial Neoplasia (CIN)1
4CompletedPreventionAIN / Human Immunodeficiency Virus (HIV) Infections1
4CompletedPreventionCervical Cancers2
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Human Papillomavirus (HPV)1
4CompletedPreventionHuman Papillomavirus (HPV)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular
SuspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:03 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates